When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
INCY - Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
Incyte Corporation
The U.S. Food and Drug Administration (FDA) recently issued a complete response letter for Incyte 's (NASDAQ: INCY) PD-1 drug retifanlimab. The PD-1 and PD-L1 immunotherapy market was already getting crowded with eight drugs already approved in the U.S. In this Motley Fool Live video recorded on July 28 , Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the PD-(L)1 party is over after Incyte's FDA rejection.